Carina Carvalho‐Maia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carina Carvalho‐Maia has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Jerónimo
Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (P.CCC)
2 shared publications Ana Paula Silva
Institute of Pharmacology and Experimental Therapeutics, Faculty of Medicine University of Coimbra Coimbra Portugal
1 shared publication- Ana Sofia Ribeiro
Cancer Metastasis, i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal
1 shared publication - Célia Gomes
Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal
1 shared publication - Eunice R. Silva
Psychology Service Portuguese Institute of Oncology of Porto Francisco Gentil, E.P.E. Porto Portugal
1 shared publication Fernando Schmitt
IPATIMUP – Institute of Molecular Pathology and Immunology of the University of Porto Porto Portugal
1 shared publication
Latest Publications
- 29 July 2024
- Published by Wiley in The Journal of Pathology
- Vol. 264 (2) , 132-147
Nerve growth factor inducible (VGF) is a secreted mediator for metastatic breast cancer tropism to the brain
Brain metastases are one of the most serious clinical problems in breast cancer (BC) progression, associated with lower survival rates and a lack of effective therapies. Thus, to dissect the early stages of the brain metastatic process, we studied the impact of brain organotropic BC cells’ secretomes on the establishment of the brain pre‐metastatic niche (PMN). We found that BC cells with specific tropism to the brain caused significant blood–brain barrier (BBB) disruption, as well as microglial activation, in both in vitro and in vivo models. Further, we searched for a brain‐organotropic metastatic signature, as a promising source for the discovery of new biomarkers involved in brain metastatic progression. Of relevance, we identified VGF (nerve growth factor inducible) as a key mediator in this process, also impacting the BBB and microglial functions both in vitro and in vivo. In a series of human breast tumors, VGF was found to be expressed in both cancer cells and the adjacent stroma. Importantly, VGF‐positive tumors showed a significantly worse prognosis and were associated with HER2 (human epidermal growth factor receptor 2) overexpression and triple‐negative molecular signatures. Further clinical validation in primary tumors from metastatic BC cases showed a significant association between VGF and the brain metastatic location, clearly and significantly impacting on the prognosis of BC patients with brain metastasis. In conclusion, our study reveals a unique secretome signature for BC with a tropism for the brain, highlighting VGF as a crucial mediator in this process. Furthermore, its specific impact as a poor prognostic predictor for BC patients with brain metastasis opens new avenues to target VGF to control the progression of brain metastatic disease. © 2024 The Pathological Society of Great Britain and Ireland.
- 29 July 2024
- Published by Wiley in The Journal of Pathology
- Vol. 264 (2) , 132-147
Nerve growth factor inducible (VGF) is a secreted mediator for metastatic breast cancer tropism to the brain
Brain metastases are one of the most serious clinical problems in breast cancer (BC) progression, associated with lower survival rates and a lack of effective therapies. Thus, to dissect the early stages of the brain metastatic process, we studied the impact of brain organotropic BC cells’ secretomes on the establishment of the brain pre‐metastatic niche (PMN). We found that BC cells with specific tropism to the brain caused significant blood–brain barrier (BBB) disruption, as well as microglial activation, in both in vitro and in vivo models. Further, we searched for a brain‐organotropic metastatic signature, as a promising source for the discovery of new biomarkers involved in brain metastatic progression. Of relevance, we identified VGF (nerve growth factor inducible) as a key mediator in this process, also impacting the BBB and microglial functions both in vitro and in vivo. In a series of human breast tumors, VGF was found to be expressed in both cancer cells and the adjacent stroma. Importantly, VGF‐positive tumors showed a significantly worse prognosis and were associated with HER2 (human epidermal growth factor receptor 2) overexpression and triple‐negative molecular signatures. Further clinical validation in primary tumors from metastatic BC cases showed a significant association between VGF and the brain metastatic location, clearly and significantly impacting on the prognosis of BC patients with brain metastasis. In conclusion, our study reveals a unique secretome signature for BC with a tropism for the brain, highlighting VGF as a crucial mediator in this process. Furthermore, its specific impact as a poor prognostic predictor for BC patients with brain metastasis opens new avenues to target VGF to control the progression of brain metastatic disease. © 2024 The Pathological Society of Great Britain and Ireland.
- Open Access
- 20 July 2021
- Published by Wiley in Psycho-Oncology
- Vol. 30 (11) , 1836-1848
Evidence of psychological and biological effects of structured Mindfulness‐Based Interventions for cancer patients and survivors: A meta‐review
Objective: A large number of studies have been conducted exploring the effects of mindfulness programs on health outcomes, such as psychological and biological outcomes. However, there is substantial heterogeneity among studies and, consequently, in the systematic reviews/meta‐analyses. Since clinical practice is massively informed by evidence on review studies, our main objective was to summarize the reported evidence regarding the effects of structured mindfulness‐based programs on psychological, biological, and quality‐of‐life outcomes in cancer patients.Methods: We conducted a meta‐review, using a literature search from inception to June 2020 in several electronic databases using a combination of keywords including MBSR, MBCT, cancer, and meta‐analysis OR “systematic review” (PROSPERO registration CRD42020186511).Results: Ten studies met the eligibility criteria and were included. The main findings were beneficial small to medium effect sizes of Mindfulness‐Based Stress Reduction (MBSR)/Mindfulness‐Based Cognitive Therapy (MBCT)/Mindfulness‐Based Cancer Recovery (MBCR) on psychological health, such as anxiety, depression, stress, and quality of life. A beneficial effect was found for biological outcomes, albeit based on a reduced number of studies. Studies were moderate homogenous regarding the intervention, population, and outcomes explored. Results on long‐term follow‐up seem to indicate that the effects tend not to be maintained, namely in shorter follow‐ups (6 months).Conclusions: This meta‐review brings a broad perspective on the actual evidence regarding MBSR/MBCT/MBCR. We expect to contribute to future project design, focused on developing high‐quality studies and exploring the moderating effects that might contribute to biased results, as well as exploring who might benefit more from MBSR/MBCT/MBCT interventions.
- 20 July 2021
- Published by Wiley in Psycho-Oncology
- Vol. 30 (11) , 1836-1848
Open AccessEvidence of psychological and biological effects of structured Mindfulness‐Based Interventions for cancer patients and survivors: A meta‐review
Objective: A large number of studies have been conducted exploring the effects of mindfulness programs on health outcomes, such as psychological and biological outcomes. However, there is substantial heterogeneity among studies and, consequently, in the systematic reviews/meta‐analyses. Since clinical practice is massively informed by evidence on review studies, our main objective was to summarize the reported evidence regarding the effects of structured mindfulness‐based programs on psychological, biological, and quality‐of‐life outcomes in cancer patients.Methods: We conducted a meta‐review, using a literature search from inception to June 2020 in several electronic databases using a combination of keywords including MBSR, MBCT, cancer, and meta‐analysis OR “systematic review” (PROSPERO registration CRD42020186511).Results: Ten studies met the eligibility criteria and were included. The main findings were beneficial small to medium effect sizes of Mindfulness‐Based Stress Reduction (MBSR)/Mindfulness‐Based Cognitive Therapy (MBCT)/Mindfulness‐Based Cancer Recovery (MBCR) on psychological health, such as anxiety, depression, stress, and quality of life. A beneficial effect was found for biological outcomes, albeit based on a reduced number of studies. Studies were moderate homogenous regarding the intervention, population, and outcomes explored. Results on long‐term follow‐up seem to indicate that the effects tend not to be maintained, namely in shorter follow‐ups (6 months).Conclusions: This meta‐review brings a broad perspective on the actual evidence regarding MBSR/MBCT/MBCR. We expect to contribute to future project design, focused on developing high‐quality studies and exploring the moderating effects that might contribute to biased results, as well as exploring who might benefit more from MBSR/MBCT/MBCT interventions.